Among all adjuvants available for cancer vaccines, we selected the TL3 agonist Poly I:C because dendritic cell 1 (cDC1) expresses TLR3, and its activation results in the induction of cytotoxic CD8+ T cells, which are crucial for an anti-tumor response [41,42]. Here, CD8A is linked to cancer.